Biolegio, established in 1996 and headquartered in The Netherlands, is a pioneering company specializing in the custom synthesis of oligonucleotides. Operating at the intersection of Analytics, Biotechnology, and Health Care, Biolegio empowers researchers globally to make strides in life sciences and molecular diagnostics. Their commitment to scientific advancement is encapsulated in their slogan: "Building the Bases of Discovery."
For over two decades, Biolegio has established itself as a trusted partner for those in need of reliable oligonucleotide supply. Despite the absence of recent investment rounds, the company’s longstanding presence and expertise in the industry underline its stability and potential for growth. With a mission to foster scientific innovation worldwide, they present a compelling opportunity for investors interested in supporting the foundational elements of cutting-edge research and diagnostics.